|
Feb 24
|
Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th
|
|
Feb 23
|
Recursion Pharmaceuticals, Inc. (RXRX): The Best Performing Pharma Stock So Far in 2025?
|
|
Feb 21
|
Cathie Wood Explains Why She Likes Recursion Pharmaceuticals, Inc. (RXRX)
|
|
Feb 19
|
Why Recursion Pharmaceuticals, Inc. (RXRX) is the Best Performing Healthcare Stock So Far in 2025
|
|
Feb 19
|
Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City
|
|
Feb 19
|
Recursion CEO launches pre-seed fund in response to NIH cuts
|
|
Feb 18
|
Recursion Pharmaceuticals Stock Scores RS Ratings Over 90
|
|
Feb 18
|
Why Jensen Huang’s Company Is Betting On Recursion Pharmaceuticals, Inc. (RXRX)
|
|
Feb 18
|
Altitude Lab Startups Raise $154M in Capital
|
|
Feb 18
|
Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock
|
|
Feb 17
|
Why Recursion Pharmaceuticals, Inc. (RXRX) Soared Last Week
|
|
Oct 8
|
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
|
|
Oct 7
|
2 Artificial Intelligence Stocks That Could Deliver Explosive Gains
|
|
Oct 2
|
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts
|
|
Oct 2
|
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
|
|
Sep 29
|
2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk
|
|
Sep 12
|
Recursion Pharmaceuticals, Inc. (RXRX): A Very Important AI Stock According to BlackRock
|
|
Sep 8
|
Recursion Pharmaceuticals, Inc. (RXRX): Among the Worst ARK Stocks According to Short Sellers
|
|
Aug 30
|
Is Recursion Pharmaceuticals a Warren Buffett Stock?
|
|
Aug 28
|
Recursion Pharmaceuticals Inc. (RXRX): Among The Best Medical AI Companies
|